HIV And Parasitic Infection (HAPI) Study

HIV Coinfection Clinical Trial

— HAPI  

Official title:

Impact of Parasitic Infections on Intestinal Epithelial Barrier and Immune Activation Among Persons Living With HIV in Lilongwe, Malawi

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05323396
• Other study ID #: 21-2553
• Secondary ID: D43TW009340
• Status: Completed
• Phase: N/A
• Start date: May 2, 2022
• Est. completion date: August 4, 2023

Study information

• Verified date: January 2024
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of this study is to determine if periodic de-worming of persons living with HIV in intestinal parasite-endemic regions will lead to decreased morbidity and mortality associated with HIV by reducing immune activation and intestinal damage associated with these diseases. The hypothesis for this project is that intestinal parasitic infections contribute to a modifiable pro-inflammatory state in persons living with HIV (PLWH).

Aim 1: Determine the prevalence of intestinal parasitic infections in PLWH receiving care at an HIV-treatment center in Lilongwe, Malawi using a highly sensitive multi-parallel stool PCR test. Hypothesis: highly sensitive stool PCR testing will demonstrate that disease burden of parasitic infection in PLWH in Malawi is higher than historically reported based on stool microscopy.

Aim 2: Determine the impact of parasitic infection on intestinal damage and immune activation by measuring sCD14, sCD163, and intestinal fatty acid binding protein (I-FABP) in PLWH. Hypothesis: plasma biomarkers reflecting intestinal damage and immune activation are elevated in those with HIV and parasitic co-infection compared with parasite-negative participants with HIV.

Aim 3: Determine the impact of eradication of parasitic infection on intestinal damage and immune activation by measuring sCD14, sCD163, and intestinal fatty acid binding protein (I-FABP) in PLWH before and after treatment of parasitic co-infection. Hypothesis: plasma biomarkers reflecting intestinal damage and immune activation are elevated in those with HIV and parasitic co-infection, and these biomarkers decrease with anti-parasitic treatment.

Description:

This is a prospective study in which participants will be enrolled in outpatient HIV clinics associated with Kamuzu Central Hospital in Lilongwe, Malawi, where there are over 25,000 patients in care with over 90% virally suppressed on ART.

Any subject meeting inclusion criteria and lacking exclusion criteria who is currently receiving care at the clinics affiliated with Kamuzu Central Hospital or Bwaila Hospital will be eligible to participate in this study. After informed consent is signed, a total of 10ml of blood, 20g stool sample, and 20mL urine sample will be collected. Each participant will be asked a series of questions. Clinical variables including age, sex, CD4+ T-cell count, and CD4% will be collected from the participant's medical chart.

Stool samples will be processed by stool microscopy in the local UNC Project Malawi laboratory, and the remaining sample will be stored at -80 degrees Celcius (C) until transported to the Laboratory of Parasitology National School of Tropical Medicine Baylor College of Medicine in Houston, Texas for detection of 9 different parasites and quantification of parasite burden by stool qPCR. Blood samples will be collected in EDTA-blood collection tubes and centrifuged. Plasma will be frozen at -80 degrees C at UNC Project Malawi until transport to the National School of Tropical Medicine Baylor College of Medicine for determination of levels of immune activation and gut mucosal impairment (sCD14, sCD163, and I-FABP) and Strongyloides stercoralis IgG. Urine samples will be evaluated by microscopy to look for Schistosoma haematobium at UNC Project Malawi laboratory.

Multi-parallel real-time quantitative PCR (qPCR) performed on stool will evaluate for 9 different parasites including Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, Schistosoma mansonii, Strongyloides stercoralis, Taenia solium, Trichuris trichiura, Entamoeba histolytica, and Giardia lamblia.

Participants that test positive for parasitic infection will be contacted and appropriate treatment administered according to the local standard of care. Albendazole single 400mg dose will be given for infection with Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, Trichuris trichiura. Albendazole 400mg daily for 5 days will be given for Strongyloides stercoralis. Praziquantel single dose 40mg/kg will be given for infection with Schistosoma mansoni and Schistosoma haematobium. Praziquantel single dose 10mg/kg will be given to treat intestinal infection with Taenia solium. Metronidazole 500mg two times a day x5 days for Giardia lamblia and 500mg three times a day x7 days for Entamoeba histolytica.

Follow up appointments will be performed 8-12 weeks after treatment and will include repeated blood and stool sample collection.

The study team anticipates enrollment of 100 patients in a period of 8-12 weeks. With an estimated intestinal parasite prevalence of 30%, the study team predicts 30 cases and 70 controls will be enrolled. Participants found to be positive at both the initial and follow up visit will be considered reinfected rather than treatment failure. These will be included in the analysis of prevalence, but the change in markers of immune activation will not be measured in this group since parasite clearance not established. Using Student's unpaired t-test to compare mean values of biomarkers between study groups, there will be 80% power to detect a difference of 0.434 x106 pg/ml, 0.56 mg/l, and 598 pg/ml between groups for biomarkers sCD14, sCD163, and I-FABP, respectively with effect sizes within the range of prior studies. Using paired t-tests to compare pre- and post-treatment biomarker levels, there will be 80% power to detect post-treatment changes of 0.317 x106/ml, 0.41 mg/l, and 435 pg/ml in sCD14, CD163, and I-FABP respectively.

Clinical variables including age, sex, and most recent CD4 count will be recorded. Clinical predictors of parasitic infection (eg CD4%) will be determined using multivariable logistical regression. Univariable linear regression will be used to determine associations between markers of immune activation (continuous outcome variable) and predictors including the clinical variables above as well as presence of multiple parasitic infections.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: August 4, 2023
• Est. primary completion date: August 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• currently living in Malawi

• HIV-1 infection

• on ART = 1 year with undetectable HIV RNA level at the last evaluation

• willingness to be treated with anti-parasitic therapy if infection with intestinal parasite is identified.

Exclusion Criteria:

• Use of antibiotics other than prophylaxis with trimethoprim-sulfamethoxazole within 60 days of screening

• Use of antiparasitic medication (ex- albendazole, praziquantel, metronidazole) in the last year

• Inflammatory bowel disease

• Gastrointestinal tract malignancy

• Major intestinal surgery during prior 2 years

• Coinfection with Mycobacterium tuberculosis

• Pregnancy, breastfeeding mother, or planning pregnancy.

Related Conditions & MeSH terms

• Coinfection
• HIV Coinfection
• HIV Infections
• Infections
• Parasitic Diseases

Intervention

Drug:
• Antiparasitic medication
Participants in the "parasite-positive" group (based on positive result of either stool microscopy, stool PCR, or Strongyloides IgG) will be administered antiparasitic treatment. Antiparasitic medication administered will be targeted to treat the parasite identified. See detailed description of protocol for medication, dose, and frequency that will be given for each parasitic infection identified. Participants with stool microscopy, stool PCR, and Strongyloides IgG all negative will not be administered treatment, thus will serve as controls.

Locations

Country	Name	City	State
Malawi	Lighthouse Clinic	Lilongwe

Sponsors (2)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill	Fogarty International Center of the National Institute of Health

Country where clinical trial is conducted

Malawi, 

References & Publications (3)

Cheru LT, Park EA, Saylor CF, Burdo TH, Fitch KV, Looby S, Weiner J, Robinson JA, Hubbard J, Torriani M, Lo J. I-FABP Is Higher in People With Chronic HIV Than Elite Controllers, Related to Sugar and Fatty Acid Intake and Inversely Related to Body Fat in People With HIV. Open Forum Infect Dis. 2018 Nov 5;5(11):ofy288. doi: 10.1093/ofid/ofy288. eCollection 2018 Nov. — View Citation

Knudsen TB, Ertner G, Petersen J, Moller HJ, Moestrup SK, Eugen-Olsen J, Kronborg G, Benfield T. Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. J Infect Dis. 2016 Oct 15;214(8):1198-204. doi: 10.1093/infdis/jiw263. Epub 2016 Jun 28. — View Citation

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15;203(6):780-90. doi: 10.1093/infdis/jiq118. Epub 2011 Jan 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of participants with intestinal parasitic infection	The prevalence of participants with intestinal parasitic infection will be determined based on the number of parasite-positive participants divided by the total number of participants.	Baseline
Primary	Mean soluble CD14 (sCD14) levels	The level of sCD14 detected in plasma will be measured in all patients at the baseline visit. The mean level of sCD14 of the parasite-positive group will be compared to the mean level of sCD14 of the parasite-negative group (pg/mL) using Student's unpaired t-test.	Baseline
Primary	Mean soluble CD163 (sCD163) levels	The level of sCD163 detected in plasma will be measured in all patients at the baseline visit. The mean level of sCD163 of the parasite-positive group will be compared to the mean level of sCD163 of the parasite-negative group (mg/L) using Student's unpaired t-test.	Baseline
Primary	Mean Intestinal Fatty-acid Binding Protein (I-FABP) levels	The level of I-FABP detected in plasma will be measured in all patients at the baseline visit. The mean level of I-FABP of the parasite-positive group will be compared to the mean level of I-FABP of the parasite-negative group (pg/mL) using Student's unpaired t-test.	Baseline
Primary	Change in sCD14 levels pre- and post-treatment	The level of sCD14 detected in plasma will be measured in all patients at the initial visit and the follow-up visit (pg/mL). The change in sCD14 pre-treatment and post-treatment levels of the parasite-positive group will be compared to the change in sCD14 pre- and post-treatment levels of the parasite-negative participants.	Baseline, 6 months after baseline visit
Primary	Change in sCD163 levels pre- and post-treatment	The level of sCD163 detected in plasma will be measured in all patients at the initial visit and the follow-up visit (mg/L). The change in sCD163 pre-treatment and post-treatment levels of the parasite-positive group will be compared to the change in sCD163 pre- and post-treatment levels of the parasite-negative participants.	Baseline, 6 months after baseline visit
Primary	Change in I-FABP levels pre- and post-treatment	The level of I-FABP detected in plasma will be measured in all patients at the initial visit and the follow-up visit (pg/mL). The change in I-FABP pre-treatment and post-treatment levels of the parasite-positive group will be compared to the change in I-FABP pre- and post-treatment levels of the parasite-negative participants.	Baseline, 6 months after baseline visit